We are live on ! Find out more
CLPT icon

ClearPoint Neuro

6.91 USD
-0.40
5.47%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
7.06
+0.15
2.17%
1 day
-5.47%
5 days
-16.95%
1 month
-26.88%
3 months
-54.51%
6 months
-38.3%
Year to date
-50.75%
1 year
-48.85%
5 years
-49.67%
10 years
77.18%
 

About: ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.

Employees: 172

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 5.3%
Neutral 89.5%
Negative 5.3%
Neutral
PRNewsWire
9 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
GlobeNewsWire
11 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Positive
Seeking Alpha
13 days ago
ClearPoint Neuro: Momentum Building Across The Business
ClearPoint Neuro (CLPT) delivered solid Q3 results, with CAL service revenue ramping and capital equipment sales providing encouraging signs of future disposables growth. Multiple Phase III trials are also expected in 2027, which should support drug-delivery revenue. Uncertainty about the prospects of uniQure's AMT-130 is weighing on the stock though.
ClearPoint Neuro: Momentum Building Across The Business
Neutral
PRNewsWire
16 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
GlobeNewsWire
18 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
PRNewsWire
23 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
MarketBeat
24 days ago
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call
ClearPoint Neuro NASDAQ: CLPT reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesses. Management said the company is investing in clinical support, laboratory capabilities and product development as it prepares for anticipated cell and gene therapy trial activity and potential commercial launches.
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call
Negative
Zacks Investment Research
24 days ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.21 per share a year ago.
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Seeking Alpha
24 days ago
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
25 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Price charts implemented using Lightweight Charts™